Sodium channel protein type 4 subunit alpha (Nav1.4), Sodium channel protein type 10 subunit alpha (Nav1.8), and Sodium channel protein type 11 subunit alpha (Nav1.9) (Nav1.4, Nav1.8, and Nav1.9)

Voltage-gated sodium channels (Nav) are essential transmembrane proteins that mediate the rapid influx of sodium ions, which is critical for the initiation and propagation of action potentials in excitable cells. This specific target profile encompasses three distinct isoforms: Nav1.4 (encoded by SCN4A), Nav1.8 (SCN10A), and Nav1.9 (SCN11A). Nav1.4 is primarily expressed in skeletal muscle, where it is indispensable for muscle contraction and neuromuscular signaling (UniProt: P35499). In contrast, Nav1.8 and Nav1.9 are predominantly localized in the peripheral nervous system, specifically within nociceptive neurons of the dorsal root ganglia, where they serve as key regulators of pain threshold and transmission (PubMed: 30104732). Mutations in these channels are linked to various channelopathies; SCN4A mutations cause periodic paralysis and myotonia, while SCN10A and SCN11A mutations are associated with small fiber neuropathy and altered pain sensitivity (StatPearls: NBK540971). Therapeutic strategies targeting Nav1.8 and Nav1.9 aim to provide analgesia for chronic and neuropathic pain, with selective inhibitors like suzetrigine (VX-548) designed to avoid the muscle weakness associated with off-target Nav1.4 inhibition (Vertex Pharmaceuticals, 2024). Non-selective sodium channel blockers, such as lidocaine and mexiletine, interact with these channels but often carry dose-limiting side effects due to their lack of isoform specificity.

Other names

SCN4ASCN10ASCN11ASkM1PN3SNSNaNSNS-2

Inhibition of voltage-gated sodium ion influx through the channel pore and stabilization of the inactivated state of the channel.